FDA Selects Moderna's Rare Disease Candidate For Accelerated Development Program
Portfolio Pulse from Vandana Singh
The FDA has selected Moderna's investigational therapeutic mRNA-3705 for the START pilot program, which aims to accelerate the development of treatments for rare diseases. This selection will enhance communication with the FDA and expedite the development of mRNA-3705, which is being investigated for methylmalonic acidemia (MMA).
June 06, 2024 | 1:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna's mRNA-3705 has been selected for the FDA's START pilot program, which will accelerate its development for treating methylmalonic acidemia. This selection is likely to enhance communication with the FDA and expedite the development process, potentially leading to earlier market entry.
The FDA's selection of mRNA-3705 for the START pilot program is a significant milestone for Moderna. This will likely lead to faster development and regulatory approval, positively impacting the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100